FAIR VALUE MEASUREMENTS (Tables)
|
9 Months Ended |
Jan. 31, 2026 |
|---|
| Fair Value Disclosures [Abstract] |
|
| Schedule of fair value of financial liabilities |
| Schedule of fair value of financial liabilities |
|
|
|
|
|
|
| Description |
|
Level |
|
January 31, 2026 |
|
April 30, 2025 |
| Liabilities: |
|
|
|
|
|
|
|
|
|
|
|
|
| Warrant liabilities |
|
|
3 |
|
|
$ |
13,657,000 |
|
|
$ |
338,000 |
|
| Derivative liabilities |
|
|
3 |
|
|
$ |
1,136,000 |
|
|
$ |
– |
|
|
| Schedule of change in the fair value warrant liability |
| Schedule of change in the fair value warrant liability |
|
|
| |
|
Three Months Ended January 31, 2026 |
| Balance on October 31, 2025 |
|
$ |
16,152,000 |
|
| Issuance of warrants |
|
|
– |
|
| Warrant exercises |
|
|
(599,135 |
) |
| Change in fair value of warrant liability |
|
|
(1,895,865 |
) |
| Balance on January 31, 2026 |
|
$ |
13,657,000 |
|
| |
|
|
Nine Months Ended January 31, 2026 |
|
| Balance on April 30, 2025 |
|
$ |
338,000 |
|
| Issuance of warrants |
|
|
5,583,000 |
|
| Warrant exercises |
|
|
(599,135 |
) |
| Change in fair value of warrant liability |
|
|
8,335,135 |
|
| Balance on January 31, 2026 |
|
$ |
13,657,000 |
|
|
| Schedule of change in the fair value derivative liability |
| Schedule of change in the fair value derivative liability |
|
|
|
| |
|
Three Months Ended January 31, 2026 |
|
| Balance on October 31, 2025 |
|
$ |
1,693,000 |
|
| Issuance of Series C convertible preferred stock |
|
|
– |
|
| Change in fair value of derivative liability |
|
|
(557,000 |
) |
| Balance on January 31, 2026 |
|
$ |
1,136,000 |
|
| |
|
Nine Months Ended January 31, 2026 |
|
| Balance on April 30, 2025 |
|
$ |
– |
|
| Issuance of Series C convertible preferred stock |
|
|
1,995,000 |
|
| Change in fair value of derivative liability |
|
|
(859,000 |
) |
| Balance on January 31, 2026 |
|
$ |
1,136,000 |
|
|
| Schedule of fair values of financial instruments by class |
| Schedule of fair values of financial instruments by class |
|
|
|
|
|
|
| |
|
|
|
|
|
|
| |
|
Level |
|
January 31, 2026 |
|
April 30, 2025 |
| Financial Assets |
|
|
|
|
|
|
|
|
|
|
|
|
| Marketable equity securities |
|
|
1 |
|
|
$ |
372,251 |
|
|
$ |
366,316 |
|
| Money market account |
|
|
1 |
|
|
$ |
2,081,636 |
|
|
$ |
76,287 |
|
| Convertible note receivable – investment in debt security - Femasys |
|
|
3 |
|
|
$ |
– |
|
|
$ |
3,696,000 |
|
| Warrant asset - Femasys |
|
|
3 |
|
|
$ |
906,000 |
|
|
$ |
3,061,000 |
|
| Investment in preferred stock - QCLS |
|
|
3 |
|
|
$ |
22,472,000 |
|
|
$ |
22,474,000 |
|
| Warrant assets - QCLS |
|
|
3 |
|
|
$ |
10,242,000 |
|
|
$ |
8,618,000 |
|
|